IUB(TM) SCu300B - Post Marketing Performance Study in Austria
NCT02778061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2020-09-25
Summary
Participating investigators will locate all IUB B insertions conducted at their facility at least 12 month prior the initiation of study data collection. The study is composed of 2 parts. Part one is collecting data out of patient's medical record which is accessible only to the doctor. This data is mostly demographic. Part two of the study comprises a phone call to the patients done by the doctor or by authorized site personnel. In the phone call the study purpose will be explained to the patient and a patient consent will be required. After the patients consent to participate, the doctor will ask the patient the questions defined in the study protocol regarding her experience during the time since the IUB SCu300B's insertion.
A total of 200 eligible subjects will be invited to participate in the study. Informed Consent Form will be signed and sent to the investigator, applicable CRFs will be completed by the investigator or authorized site personnel. The patient questionnaires will be asked on the telephone and entered directly into the CRF by the investigator or authorized site staff (CRF = source document). Also the physician´s questionnaire will be directly completed in the CRF by the investigator (CRF = source document). All other clinical data will be transcribed to the CRF from the medical patient records (patient records = source document).
There are no planned patient visits to the doctor's office for study purposes. If the patient visits the physician´s office as part of the clinical routine, the study procedures can also be performed directly at the site instead of telephone contacts.
Conditions
- Contraception
Sponsors & Collaborators
-
Ocon Medical Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 42 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-05-31
- Primary Completion
- 2016-12-31
- Completion
- 2016-12-31
More Related Trials
-
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
NCT06384131 ·Status: COMPLETED ·Phase: PHASE1
-
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
NCT04904835 ·Status: COMPLETED
-
A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B
NCT00753467 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
NCT01743079 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910 ·Status: RECRUITING ·Phase: PHASE2
-
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
NCT02631096 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
NCT03576066 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
NCT04749368 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients
NCT01027065 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
NCT00124241 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
NCT05717686 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B
NCT00907894 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100 ·Status: RECRUITING
-
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
NCT01651403 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of LW231 in Participants With Chronic Hepatitis B
NCT07179575 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
NCT00132652 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
NCT03109730 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037 ·Status: RECRUITING
-
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
NCT05242445 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
NCT02751996 ·Status: COMPLETED ·Phase: PHASE2
-
Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.
NCT06347588 ·Status: ACTIVE_NOT_RECRUITING
-
A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
NCT02908191 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
NCT05414981 ·Status: COMPLETED ·Phase: PHASE1
-
Towards a Functional Cure for HBV - The COMMIT Cohort Study
NCT03645044 ·Status: ACTIVE_NOT_RECRUITING
-
Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine
NCT01005238 ·Status: TERMINATED ·Phase: PHASE4